Antiplatelet therapy in high-risk patients with acute coronary syndromes – Current evidence and future directions

Event: ESC CONGRESS 2014
Topic: Thrombosis and platelets
Session type: EBAC Accredited Educational Programme
Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca
Date: 30 August 2014
Time: 15:30 - 17:00

8 presentations in this session

Introduction and objectives - Antiplatelet therapy in high-risk patients with ACS.

Speaker: Doctor A. Fernandez Ortiz (Madrid, ES)
Thumbnail

Early initiation of antiplatelet therapy - Recommendations and current practice.

Speaker: Professor P. Steg (Paris, FR)
Thumbnail

Discussion - Early initiation of antiplatelet therapy.

Thumbnail

Thienopyridines and ticagrelor – New pharmacological evidence and clinical effects.

Speaker: Professor R. Storey (Sheffield, GB)
Thumbnail

Discussion - Thienopyridines and ticagrelor.

Thumbnail

Optimising duration of antiplatelet therapy following acute coronary syndrome.

Speaker: Professor P. Serruys (Galway, IE)
Thumbnail

Discussion - Optimising duration of antiplatelet therapy following ACS.

Thumbnail

Summary and close - Antiplatelet therapy in high-risk patients with ACS.

Speaker: Professor F. Van de Werf (Leuven, BE)
Thumbnail

5 speakers from this session

Doctor Antonio Ignacio Fernandez Ortiz

San Carlos Clinical University Hospital, Madrid (Spain)
0 follower

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)
46 presentations
2 followers

Professor Robert Storey

Department of Cardiovascular Science, University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)
17 presentations
1 follower

Professor Patrick Washington Serruys

National University of Ireland, Galway (Ireland)
14 presentations
0 follower

Professor Frans Van de Werf

University of Leuven, Leuven (Belgium)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk